BioSpace News Archive

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update on recent progress with its two pipeline assets, paxalisib and EVT801

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced that the first patient in Canada has been treated with the CellFX procedure.

Riverside Research welcomes Dr. Rob Denz as the new Director of the Trusted and Resilient Systems Group, a part of the Open Innovation Center.

Biocom California Institute, a 501(c)(3) non-profit that supports life science innovation by strengthening the workforce and leaders of tomorrow, announced that it has added Susie Harborth, executive vice president of business operations at Breakthrough Properties; Stacy Solorio, vice president of human resources at Karius; Deborah Wafer, medical scientist at Gilead and Willie Zuniga, president of Grifols Biologicals to its board of directors.

XBiotech announced it received $75 million from funds escrowed as part of its December 2019 sale of bermekimab.

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the publication of results from the final analysis of a pivotal Phase 3 clinical trial of its COVID-19 vaccine candidate conducted in the United Kingdom in the New England Journal of Medicine (NEJM).

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 2 individuals hired by Sarepta in June 2021.

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the strategy for bringing rexlemestrocel-L to patients in the United States (US) with chronic low back pain (CLBP) due to degenerative disc disease (DDD) refractory to available therapies, including opioids.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of Rylaze™

Ensysce Biosciences, Inc. announced that, in connection with the closing of its previously announced merger with Leisure Acquisition Corp., the combined company, Ensysce Biosciences, Inc., will commence trading its common stock and warrants under the ticker symbols “LACQ” and “LACQW,” respectively, on the OTC Market on July 1, 2021.